Visual Acuity – Medxy AI

Breakthrough Optogenetic Therapy UGX-201 Shows Promise for Advanced Retinitis Pigmentosa

By MedXY 07/02/2026

An exploratory trial of UGX-201, a novel optogenetic therapy, demonstrated safety and meaningful visual improvements in patients with advanced nonsyndromic retinitis pigmentosa, including restoration of light perception in those previously without vision.

news Ophthalmology Public Health

Most Patients Reach 20/40 After Cataract Surgery, but the Current MIPS Success Metric May Misclassify Quality and Exclude Nearly Half of Cases

By MedXY 05/09/2026

A large multicenter study found that MIPS measure 191 captures high cataract surgery success rates but excludes many patients and may require case-mix adjustment to support fair surgeon comparisons.

Ophthalmology Specialties

Intravenous Alteplase Versus Oral Aspirin in Acute Central Retinal Artery Occlusion: Insights from the THEIA Phase 3 Trial and Contextual Evidence

By MedXY 10/22/2025

THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis benefits.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Oral Lamivudine: A Promising Alternative in the Management of Diabetic Macular Edema

By MedXY 09/17/2025

A recent randomized, double-blind trial demonstrates that oral lamivudine significantly improves visual acuity in patients with center-involved diabetic macular edema, offering a cost-effective and safer alternative to conventional anti-VEGF therapy.